VALENCIA, Calif. and BELO HORIZONTE, Brazil, May 31, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) and BIOMM SA (BVMF:BIOM3) today announced that they have entered into a supply and distribution agreement for the commercialization of Afrezza® (insulin human) Inhalation Powder in Brazil. Under the supply and distribution agreement, Biomm will be responsible for preparing and filing the necessary applications for regulatory approval of Afrezza, including from the Agência Nacional de Vigilância Sanitária and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos. Upon satisfactory approval from these regulatory bodies, MannKind will manufacture and supply Afrezza to Biomm, and Biomm will be responsible for promoting and distributing Afrezza within Brazil.
“We are pleased to partner with Biomm to bring Afrezza to the Brazilian diabetes market,” said Michael Castagna, Chief Executive Officer of MannKind Corporation. “Our founder, Alfred Mann, had a vision to reduce the global burden of diabetes through novel technologies. In 2015, more than 14 million people were estimated to have diabetes in Brazil. Given Biomm’s presence and knowledge of the diabetes market in Brazil, we believe that Biomm is the ideal partner to reach healthcare providers and patients with the message that there is another potential option in their fight against diabetes.”
“As a pioneering biotechnology company in Brazil, we believe that we can leverage our current portfolio of diabetes products to offer another option to the significant and growing numbers of patients with diabetes,” said Heraldo Marchezini, Diretor Presidente/CEO of Biomm SA. “We are proud to be the first company to bring inhaled mealtime insulin to the Brazilian market.”
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
ABOUT BIOMM SA
Biomm SA company (BOVESPA:BIOM3) is the First Brazilian Biopharmaceutical Company and the only human biotech company listed on the Brazilian BOVESPA Stock Exchange. The company is committed to making difficult to treat chronic diseases more cost effective, thereby improving the quality of life for patients. With innovation in its DNA, Biomm is pioneer in biotechnology and in the production of insulin in Brazil.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind's ability to directly commercialize pharmaceutical products. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability to obtain regulatory approvals, the ability to get satisfactory pricing terms from regulators and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.